188 related articles for article (PubMed ID: 17644120)
1. Taxane refractory prostate cancer.
Mathew P; Dipaola R
J Urol; 2007 Sep; 178(3 Pt 2):S36-41. PubMed ID: 17644120
[TBL] [Abstract][Full Text] [Related]
2. Taxane-based Combination Therapies for Metastatic Prostate Cancer.
Corn PG; Agarwal N; Araujo JC; Sonpavde G
Eur Urol Focus; 2019 May; 5(3):369-380. PubMed ID: 29275145
[TBL] [Abstract][Full Text] [Related]
3. Taxane-induced Attenuation of the CXCR2/BCL-2 Axis Sensitizes Prostate Cancer to Platinum-based Treatment.
Ruiz de Porras V; Wang XC; Palomero L; Marin-Aguilera M; Solé-Blanch C; Indacochea A; Jimenez N; Bystrup S; Bakht M; Conteduca V; Piulats JM; Buisan O; Suarez JF; Pardo JC; Castro E; Olmos D; Beltran H; Mellado B; Martinez-Balibrea E; Font A; Aytes A
Eur Urol; 2021 Jun; 79(6):722-733. PubMed ID: 33153817
[TBL] [Abstract][Full Text] [Related]
4. Taxane- and epothilone-based chemotherapy: from molecule cargo cytoskeletal logistics to management of castration-resistant prostate carcinoma.
Alberti C
Eur Rev Med Pharmacol Sci; 2013 Jun; 17(12):1658-64. PubMed ID: 23832735
[TBL] [Abstract][Full Text] [Related]
5. Taxane resistance in breast cancer: mechanisms, predictive biomarkers and circumvention strategies.
Murray S; Briasoulis E; Linardou H; Bafaloukos D; Papadimitriou C
Cancer Treat Rev; 2012 Nov; 38(7):890-903. PubMed ID: 22465195
[TBL] [Abstract][Full Text] [Related]
6. A retrospective evaluation of second-line chemotherapy response in hormone-refractory prostate carcinoma: second line taxane-based therapy after first-line epothilone-B analog ixabepilone (BMS-247550) therapy.
Rosenberg JE; Galsky MD; Rohs NC; Weinberg VK; Oh WK; Kelly WK; Small EJ
Cancer; 2006 Jan; 106(1):58-62. PubMed ID: 16329138
[TBL] [Abstract][Full Text] [Related]
7. Farnesyltransferase inhibitors reverse taxane resistance.
Marcus AI; O'Brate AM; Buey RM; Zhou J; Thomas S; Khuri FR; Andreu JM; Díaz F; Giannakakou P
Cancer Res; 2006 Sep; 66(17):8838-46. PubMed ID: 16951201
[TBL] [Abstract][Full Text] [Related]
8. Germline BRCA mutation does not prevent response to taxane-based therapy for the treatment of castration-resistant prostate cancer.
Gallagher DJ; Cronin AM; Milowsky MI; Morris MJ; Bhatia J; Scardino PT; Eastham JA; Offit K; Robson ME
BJU Int; 2012 Mar; 109(5):713-9. PubMed ID: 21756279
[TBL] [Abstract][Full Text] [Related]
9. Targeting ribosomal S6 kinases/Y-box binding protein-1 signaling improves cellular sensitivity to taxane in prostate cancer.
Shiota M; Itsumi M; Yokomizo A; Takeuchi A; Imada K; Kashiwagi E; Inokuchi J; Tatsugami K; Uchiumi T; Naito S
Prostate; 2014 Jun; 74(8):829-38. PubMed ID: 24729449
[TBL] [Abstract][Full Text] [Related]
10. Ixabepilone: a new microtubule-targeting agent for breast cancer.
Higa GM; Abraham J
Expert Rev Anticancer Ther; 2008 May; 8(5):671-81. PubMed ID: 18471040
[TBL] [Abstract][Full Text] [Related]
11. miR-130a activates apoptotic signaling through activation of caspase-8 in taxane-resistant prostate cancer cells.
Fujita Y; Kojima T; Kawakami K; Mizutani K; Kato T; Deguchi T; Ito M
Prostate; 2015 Oct; 75(14):1568-78. PubMed ID: 26074357
[TBL] [Abstract][Full Text] [Related]
12. Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes.
Oh WK; Manola J; Babcic V; Harnam N; Kantoff PW
Urology; 2006 Jun; 67(6):1235-40. PubMed ID: 16765185
[TBL] [Abstract][Full Text] [Related]
13. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
Martin SK; Kyprianou N
Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
[TBL] [Abstract][Full Text] [Related]
14. Overcoming EZH2 Inhibitor Resistance by Taxane in PTEN-Mutated Cancer.
Ma L; Yan Y; Bai Y; Yang Y; Pan Y; Gang X; Karnes RJ; Zhang J; Lv Q; Wu Q; Huang H
Theranostics; 2019; 9(17):5020-5034. PubMed ID: 31410199
[No Abstract] [Full Text] [Related]
15. Cellular bases of the antitumor activity of the novel taxane IDN 5109 (BAY59-8862) on hormone-refractory prostate cancer.
Cassinelli G; Lanzi C; Supino R; Pratesi G; Zuco V; Laccabue D; Cuccuru G; Bombardelli E; Zunino F
Clin Cancer Res; 2002 Aug; 8(8):2647-54. PubMed ID: 12171897
[TBL] [Abstract][Full Text] [Related]
16. Castration resistant, taxane naïve metastatic prostate cancer: current clinical approaches and future directions.
Gignac GA; Morris MJ; Hussain M
J Urol; 2007 Sep; 178(3 Pt 2):S30-5. PubMed ID: 17644121
[TBL] [Abstract][Full Text] [Related]
17. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel.
Ross RW; Beer TM; Jacobus S; Bubley GJ; Taplin ME; Ryan CW; Huang J; Oh WK;
Cancer; 2008 Feb; 112(3):521-6. PubMed ID: 18085595
[TBL] [Abstract][Full Text] [Related]
18. Taxane resistance in prostate cancer is mediated by decreased drug-target engagement.
Gjyrezi A; Xie F; Voznesensky O; Khanna P; Calagua C; Bai Y; Kung J; Wu J; Corey E; Montgomery B; Mace S; Gianolio DA; Bubley GJ; Balk SP; Giannakakou P; Bhatt RS
J Clin Invest; 2020 Jun; 130(6):3287-3298. PubMed ID: 32478682
[TBL] [Abstract][Full Text] [Related]
19. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
Goble S; Bear HD
Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604
[TBL] [Abstract][Full Text] [Related]
20. Cabazitaxel: more than a new taxane for metastatic castrate-resistant prostate cancer?
Mita AC; Figlin R; Mita MM
Clin Cancer Res; 2012 Dec; 18(24):6574-9. PubMed ID: 23091116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
